Form 144 notice filed for a proposed sale of 4,925 common shares. The shares are to be sold through Fidelity Brokerage Services LLC on the NYSE, with an approximate sale date of 10/27/2025. The filing lists an aggregate market value of $1,176,779.50 for the proposed sale.
The seller acquired 4,925 shares on 10/27/2025 via an option originally granted on 02/21/2020, with payment noted as cash. The filing also cites 122,394,037 shares outstanding; this is a baseline figure, not the amount being offered.
Equifax Inc. reported Q3 2025 results with operating revenue of $1,544.9 million, up 7% year over year, and operating income of $264.3 million. Diluted EPS was $1.29 versus $1.13 a year ago as segment growth offset higher SG&A and depreciation. Interest expense declined to $52.2 million.
Growth was broad-based: Workforce Solutions revenue rose to $649.4 million (+5%), U.S. Information Solutions to $530.2 million (+11%), and International to $365.3 million (+6%). Year to date, cash provided by operating activities was $1,144.9 million with capital expenditures of $349.1 million. The company repurchased $300.0 million of shares in Q3 (1.24 million shares) and paid a quarterly dividend of $0.50 per share. Total debt was $4,835.6 million with $1.4 billion available under the Revolver at September 30, 2025.
Equifax Inc. (EFX) furnished its quarterly results press release for the three months ended September 30, 2025. The company issued the release on October 21, 2025, and attached it as Exhibit 99.1. The press release is being furnished and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference into Securities Act filings unless specifically referenced.
Director Marcus Robert D. reported on Form 4 that on 09/30/2025 he was issued 132 phantom stock units under Equifax Inc.'s deferred compensation plan in lieu of his annual cash retainer. Each phantom unit is the economic equivalent of one share of common stock and is valued in the filing at $256.53 per share. Following the award, the reporting person beneficially owns 2,127 shares directly. The filing states the phantom units become payable, at the director's election, upon termination of his board service.
Form 144 notice by an Equifax insider to sell common stock. The filer intends to sell 4,553 shares of Equifax common stock through Fidelity Brokerage Services on the NYSE, with an aggregate market value reported as $1,111,895.40 and total shares outstanding listed as 123,797,380. The securities to be sold derive from stock options granted on 11/01/2019 (722 shares) and 09/28/2018 (3,831 shares); payment is shown as cash and the approximate date of sale is 08/29/2025. The filing indicates no securities were sold by the reporting person in the past three months and includes the standard representation that the seller knows of no undisclosed material adverse information about the issuer.
Form 144 notice for Equifax, Inc. (EFX) reporting a proposed sale of 3,764 common shares with an aggregate market value of $964,649.84 to be sold on 08/22/2025 through Fidelity Brokerage Services LLC on the NYSE. The filing lists acquisition details for these shares as an option granted on 02/09/2024 with an acquisition date recorded as 08/22/2025 and payment in cash. An additional 1 share was acquired via dividend reinvestment on 06/12/2025. The filing also discloses a sale by Todd M. Horvath of 8,797 common shares on 08/20/2025 yielding $2,199,425.94. The notice includes the required representation that the seller does not possess undisclosed material adverse information about the issuer.
Equifax insider sale by EVP/CFO/COO. John W. Gamble Jr., Equifax (EFX) executive, sold 3,000 shares of Common Stock on 08/18/2025 at $247.35 per share under a pre-established Rule 10b5-1 trading plan adopted 05/14/2025. After the sale he beneficially owns 62,202 shares, which figure includes accrued dividend equivalent units reinvested into restricted stock units through the company’s last dividend payment date. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 08/20/2025.
Equifax, Incorporated (EFX) filing a Form 144 notifies a proposed sale of 8,797 common shares through Fidelity Brokerage Services on the NYSE with an aggregate market value of $2,199,425.95. The filing shows the shares to be sold on 08/20/2025. The shares were acquired by option with grant date 05/01/2023 and the acquisition/expected sale date listed as 08/20/2025, with payment in cash. Total shares outstanding reported are 123,797,380. The filer certifies no undisclosed material adverse information and provides standard Rule 144 representations.
Equifax (EFX) Form 144 notice reports a proposed sale of 3,000 common shares through Fidelity Brokerage Services with an aggregate market value of $742,050. The shares represent restricted stock that vested and were acquired on 02/23/2024 as compensation from the issuer. The filing shows 123,797,380 shares outstanding and lists an approximate sale date of 08/18/2025 on the NYSE. The filer states there were no securities sold in the past three months and makes the standard representation that they are not aware of any undisclosed material adverse information about the issuer.